Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
554.00    -2.50 (-0.45%)
Bid:
554.00
Ask:
554.50
Spread: 0.50 (0.09%)
Market Cap: £2.45b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Director/PDMR Shareholding

8 Sep 2020 10:00

RNS Number : 2647Y
Tate & Lyle PLC
08 September 2020
 

 

Tate & Lyle PLC

 

Notification of transaction by Person Discharging Managerial Responsibilities

 

Tate & Lyle PLC (the 'Company') was informed that 15,065 ordinary shares of 25 pence each in the capital of the Company ('Shares') were released on 4 September 2020 to Andrew Taylor, a Person Discharging Managerial Responsibilities, in accordance with the Restricted Share Award that was granted to him on 24 November 2017. 6,674 shares were withheld to satisfy tax obligations arising on the release of the Shares. As a result, Mr. Taylor acquired and retained a total of 8,391 Shares. For tax purposes, the market value of the Shares, being the average of the two closing prices on the date of the transaction, was 674.2 pence per share. No consideration was paid for the acquisition of these Shares.

 

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Claire-Marie O'Grady

Company Secretary

8 September 2020

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Andrew Taylor

2.

Reason for the notification

a)

Position / status

PDMR

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tate & Lyle PLC

b)

LEI

2138008K14474WPKZ244

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary shares of 25 pence each in the capital of Tate & Lyle PLC

 

GB0008754136

b)

Nature of the transaction

Acquisition of shares following the vesting of nil-cost conditional awards over shares for no consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

8,391

d)

Aggregated information

- Aggregated volume

- Price

 

 

8,391

 

Nil

e)

Date of the transaction

2020-09-04

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUBOSRRKUKRAR
Date   Source Headline
5th Jul 20245:49 pmRNSTransaction in Own Shares
5th Jul 20242:00 pmRNSDirector/PDMR Shareholding
4th Jul 20245:40 pmRNSTransaction in Own Shares
3rd Jul 20245:29 pmRNSTransaction in Own Shares
2nd Jul 20245:32 pmRNSTransaction in Own Shares
2nd Jul 202411:30 amRNSHolding(s) in Company
1st Jul 20245:29 pmRNSTransaction in Own Shares
1st Jul 202412:30 pmRNSTotal Voting Rights
28th Jun 20245:59 pmRNSTransaction in Own Shares
27th Jun 20245:37 pmRNSTransaction in Own Shares
27th Jun 20244:30 pmRNSCompletes sale of remaining interest in Primient
27th Jun 20243:30 pmRNSHolding(s) in Company
26th Jun 20245:38 pmRNSTransaction in Own Shares
25th Jun 20245:50 pmRNSTransaction in Own Shares
24th Jun 20245:35 pmRNSTransaction in Own Shares
24th Jun 20243:30 pmRNSHolding(s) in Company
21st Jun 20245:45 pmRNSTransaction in Own Shares
21st Jun 20242:45 pmRNSUpdate to the Notice of AGM 2024
20th Jun 20246:03 pmRNSTransaction in Own Shares
20th Jun 20247:05 amRNSLaunch of Share Buyback
20th Jun 20247:00 amRNSCombination of Tate & Lyle and CP Kelco
4th Jun 20245:22 pmRNSAnnual Financial Report and Notice of AGM
4th Jun 202411:00 amRNSDirector/PDMR Shareholding
3rd Jun 202412:00 pmRNSTotal Voting Rights
30th May 202412:15 pmRNSHolding(s) in Company
23rd May 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSSale of remaining interest in Primient JV to KPS
20th May 20241:00 pmRNSDirectorate Change
17th May 20243:30 pmRNSHolding(s) in Company
14th May 20243:30 pmRNSHolding(s) in Company
13th May 202410:00 amRNSHolding(s) in Company
8th May 20243:15 pmRNSHolding(s) in Company
1st May 20242:30 pmRNSTotal Voting Rights
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.